3-rx.comCustomer Support
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics

\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>

Join our Mailing List


You are here : 3-RX.com > Home > Cancer - Ovarian cancer -

At-risk screening not advised for ovarian cancer

Cancer • • Ovarian cancerFeb 24, 09

Women with mutations in the BRCA1 or BRCA2 genes are at increased risk for ovarian cancer, but new research indicates that annual screening exams are not worthwhile as they do not help detect the cancer at an early stage.

BRCA1 and BRCA2 belong to a class of genes called tumor suppressors. Both genes encode proteins that help to repair damaged chromosomes. With a mutation in the genes, the proteins cannot perform this job effectively and, therefore, genetic damage persists that may give way to uncontrolled cell growth, also known as cancer. BRCA1 and BRCA2 mutations are also well known for their association with breast cancer.

One option for women with a proven BRCA1 or BRCA2 mutation is to choose screening “with the main objective to identify ovarian cancer in an early stage to improve prognosis and reduce morbidity and mortality,” write Dr. Geertruida H. de Bock and colleagues at the University of Groningen, the Netherlands.

However, the effectiveness of such screening “was disappointing,” they report. The screening exams often missed the cancer completely and all of the ones that were detected were already at an advanced stage, according to the report in the International Journal of Cancer.

The study included 241 women with a BRCA1 or BRCA2 mutation who underwent screening at least one time between 1995 and 2006.

The screenings, which started at age 35 years or 5 years earlier than the youngest age at diagnosis of ovarian cancer in the family, involved annual pelvic examination, transvaginal ultrasound, and measurements of serum CA125, a blood test for ovarian cancer.

During a total of 470 screening visits, three ovarian cancers were detected, all in BRCA1 mutation carriers. All three were in an advanced stage.

“At this time,” de Bock and colleagues advise, “prophylactic (ovary and fallopian tube removal on both sides) from age 35-40 for BRCA1 carriers and from age 40-45 for BRCA2 carriers is the only effective strategy, as it reduces the risk of ovarian cancer by 96 percent and may also protect against breast cancer with a risk reduction up to 53 percent when performed in premenopausal women.”

They add, “For women who still want to opt for screening, a more effective screening strategy needs to be designed.”

SOURCE: International Journal of Cancer, February 15, 2009.

Print Version
comments powered by Disqus

  New biomarkers may influence drug design and alternative treatments of cancer, study shows
  Metabolic profiles distinguish early stage ovarian cancer with unprecedented accuracy
  Moffitt researchers develop first genetic test to predict tumor sensitivity to radiation therapy
  New drug for neuroblastoma shows promise in phase I study
  Experimental treatment sends deadly leukemia into remission
  Study could reduce unnecessary cancer screening
  UA researchers discover component of cinnamon prevents colorectal cancer in mice
  Profiling approach to enable right lung cancer treatment match
  Fat grafting technique improves results of breast augmentation
  Germline TP53 mutations in patients with early-onset colorectal cancer
  Clinical trial suggests combination therapy is best for low-grade brain tumors
  UW research shows sensor technology may help improve accuracy of clinical breast exams


Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site